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Abstract
Background: To provide estimations of partial and total prevalence of 24 cancer sites in France in 2008. The estimations
of partial prevalence were compared with the previous estimations for 2002.
Methods: Nationwide estimations of incidence and survival data from cancer registries were used for partial prevalence.
Nationwide incidence and mortality data were used to estimate total prevalence.
Results: At the end of 2008, in France, nearly 3 million people still alive had received a diagnosis of cancer. Of all
prevalent cases, 36% were diagnosed 0 to 5 years earlier and 43% diagnosed 6 to 10 years earlier. The cancer sites with
the highest prevalence were the prostate, the breast, and the colon-rectum. The changes in partial prevalence over
5 years (2002 to 2008) were considerable (+244,000 cases) and deemed to be highly related to changes in incidence.
Conclusion: The present estimations update the French prevalence data and highlight the burden of cancer in the
population, especially in the elderly. The methods of this study had the advantage of using recent incidence and survival
data, which is necessary to show sudden changes in incidence trends and changes in survival that impact prevalence.
Keywords: Partial prevalence, Total prevalence, Cancer burden, Incidence, Survival
Background
Cancer prevalence has been defined as the number of
persons alive who had a cancer diagnosis [1]. This preva-
lence, called total prevalence, concerns a broad and het-
erogeneous group because it groups people in complete
remission (or cured) who are no longer receiving treat-
ment together with people in need of care and surveil-
lance, be it for initial or recurrent cancer. Another
indicator, called partial prevalence, is thus needed. It is
used for a more accurate determination of prevalent
cases that need specialized healthcare [2-5].
The partial prevalence limits the total prevalence to the
persons whose diagnosis was made within a given period
of time (e.g., within 1, 3, 5, or 10 years). The meaning of
this prevalence depends on the cancer site; however, over-
all, partial prevalence at 1, 3, and 5 years may indicate the
number of people in, respectively, initial treatment,
clinical surveillance, and complete remission, [4]. Partial
prevalence at 10 years indicates mainly, but not exclu-
sively, the number of cured patients.
Although partial prevalence is an essential epidemio-
logical indicator in cancer, the number of related publica-
tions remains low [4]. Nevertheless, some global estimates
have been recently published [6].
The objective of this article is to provide estimations
of total and partial prevalence for 24 cancer sites in the
French population at end of 2008 using the most recent
incidence, mortality, and survival data.
Methods
Partial prevalence
The partial prevalence has been estimated at 1, 3, 5, and
10 years using a combination of incidence and survival
values [7]. This prevalence may be written:
Px nð Þ ¼
Xn
i¼1Ik−1  Sk−1 i−0:5ð Þ
where Ix is the annual number of new cases at age x and
Sx(t) the survival probability at time t after diagnosis of the
cases diagnosed at age x. The estimations of the National
incidence were obtained according to a modeling method
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by Belot et al. [8]. This method uses the incidence/mortal-
ity ratio relative to the area covered by 17 Département-
wide registries (nearly 20% of the French population) over
the 1975–2008 period (1975–2009 for breast and prostate
cancers) together with the National mortality data.
The overall survivals were estimated by year of age on
the basis of incident cases diagnosed between 1995 and
2004 and followed-up by 12 registries (nearly 13% of the
French population).
The vital status at 10 years (at the closing date of Janu-
ary 1, 2008) could be obtained for 97% of the patients
[9]. “All-cancer partial prevalence” was the sum of the
partial prevalence values calculated for the 24 cancer
sites (Table 1) plus the partial prevalence of all other
cancers.
The determining factors of change in the partial preva-
lence over 5 years in France between 2002 and 2008 [3]
were analyzed using the decomposition method reported
by Bashir et al. [10]. This method allows a quantification
of the net change taking into account two demographic
factors (the population size and aging) in the overall
change of the number of prevalent cases. Within the
context of prevalence, the net change results from
changes in incidence and survival.
Total prevalence
Total prevalence requires exhaustive survival data on in-
cident cases over a long period of time (or long-term
survival data), which is not available in France. Total
prevalence was then estimated using the following rela-
tionship between prevalence, incidence, and mortality
[11]. This relationship relies on the prevalence odds and
applies analytical simplifications that assume that deaths
from other causes are the same in cancer patients and
other persons [See the Appendix in Additional file 1].
The deduced prevalence p(x,u) is thus:
p x; uð Þ ¼ CI x; uð Þ−CM x; uð Þ
1−CM x; uð Þ
In this formula p(x, u) is the probability for a subject
aged x born in year u of having had a diagnosis of cancer
before age x; this corresponds to the prevalence esti-
mated at time t = u + x providing that the subject is still
alive at time t. The net risk of cancer CI(x,u) and the net
risk of death from cancer CM(x,u)) correspond, respect-
ively, to the incidence and mortality cumulated between
age 0 and age x for a cohort born in year u. These cu-
mulated risks were estimated from the specific risks
using age-cohort Poisson regression models [12] that
take into account the effects of age x and birth cohort u
using a smoothing spline [13]. This kind of modeling re-
quires long-term incidence and mortality data. The
study considered the National data available since 1975
over the 1975–2008 period; the incidence and mortality
rates relative to the period before 1975 were considered
zero. The total prevalence estimated herein is therefore
a prevalence obtained with 34 years of data. “All-cancer
total prevalence” was estimated directly from the inci-
dence and mortality values calculated for the 24 cancer
sites plus the values relative to all other cancers.
The estimations of incidence used for partial and total
prevalence correspond to all primary invasive cancers.
These estimations were obtained by considering the
number of incident cases whatever the ranks of the tu-




In 2008, the number of prevalent cases diagnosed within
the previous five years was greater than 1 million (Table 1).
In men, prostate cancer was the most frequent (nearly
285,000 cases). This concerned all age groups except the
15-44-year-olds in whom testis cancer accounted for one
quarter of the cases. In women, in all age groups, breast
cancer was the most frequent (nearly 222,000 cases). More
than half of the prevalent cases of thyroid, central nervous
system, testis, and cervical cancers plus acute leukemia
and Hodgkin disease occurred before age 55 years. For all
cancers in men and women, the 3% threshold was reached
circa age 55 years. This percentage exceeded 9% in men
aged 75 to 84 years. A percentage close to or greater than
4% was observed for prostate cancer between ages 65
and 84.
For all cancers combined, the proportion of cases diag-
nosed at least 6 years and at most 10 years before was
higher in women than in men (Figures 1 and 2). The dis-
tribution of the cases according to the time since diag-
nosis varied with the cancer site. For good prognosis
cancers (testis, breast, thyroid in women, and Hodgkin
disease), the partial prevalence at 1 year accounted for
less than 14% of the partial prevalence at 10 years and
the prevalence between 6 and 10 years exceeded 40% of
the partial prevalence at ten years. For poor prognosis
cancers (pancreas, liver, esophagus, lung), the partial
prevalence at 1 year exceeded 30% whereas the partial
prevalence between 6 and 10 years ranged between 15
and 25%.
From 2002 to 2008, the5-years partial prevalence of all
cancers increased by 37.7% in men and 20.8% in women
(i.e., 159,000 and 83,000 cases, respectively; Table 2) which
corresponds to a net increase in prevalence of +25.9% in
men and +11.3% in women. These increases were mainly
due to increases in prostate and breast cancers. The net
changes were similar in men and women: decreases of
stomach cancers, slight increases in colon-rectum and
bladder cancers, and strong increases in liver, pancreas,
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Table 1 Partial cancer prevalence at five years by sex and age of the adult French population
Sex and site [15;44] [45;54] [55;64] [65;74] [75;84] 85 + 15-85+
Men
Lip, oral cavity, pharynx 1118 (9.1)* 5903 (142.7) 9842 (263.1) 4998 (217.4) 2954 (186.2) 656 (140.5) 25470 (104.1)
Esophagus 77 (0.6) 819 (19.8) 2008 (53.7) 1529 (66.5) 1054 (66.4) 169 (36.2) 5655 (23.1)
Stomach 252 (2.1) 747 (18.1) 1568 (41.9) 2152 (93.6) 2094 (132.0) 634 (135.9) 7448 (30.5)
Colon-rectum 1417 (11.6) 4758 (115.0) 14325 (382.9) 19220 (836.1) 19376 (1221.0) 5202 (1114.5) 64297 (262.9)
Liver 161 (1.3) 575 (13.9) 1992 (53.2) 2648 (115.2) 1788 (112.7) 195 (41.7) 7359 (30.1)
Pancreas 139 (1.1) 411 (9.9) 962 (25.7) 1134 (49.3) 768 (48.4) 179 (38.3) 3592 (14.7)
Larynx 258 (2.1) 1827 (44.2) 3862 (103.2) 2757 (119.9) 1664 (104.9) 315 (67.5) 10684 (43.7)
Lung 858 (7.0) 5063 (122.4) 11785 (315.0) 10835 (471.3) 6369 (401.3) 780 (167.2) 35690 (145.9)
Skin melanoma 3125 (25.6) 2765 (66.8) 4032 (107.8) 3750 (163.1) 3268 (206.0) 952 (204.1) 17893 (73.2)
Prostate 104 (0.8) 6119 (147.9) 63906 (1708.3) 105131 (4573.0) 76298 (4808.2) 13801 (2957.1) 265359 (1085.0)
Testis 7252 (59.3) 1638 (39.6) 586 (15.7) 180 (7.8) 72 (4.5) 33 (7.1) 9761 (39.9)
Bladder 229 (1.9) 1572 (38.0) 5899 (157.7) 7842 (341.2) 8446 (532.2) 2356 (504.8) 26344 (107.7)
Kidney 1021 (8.3) 2827 (68.4) 5747 (153.6) 6021 (261.9) 4823 (304.0) 933 (199.9) 21372 (87.4)
Brain, CNS 1224 (10.0) 709 (17.1) 804 (21.5) 465 (20.2) 232 (14.6) 72 (15.4) 3505 (14.3)
Thyroid 2050 (16.8) 1614 (39.0) 2061 (55.1) 1098 (47.7) 479 (30.2) 76 (16.3) 7378 (30.2)
Non-Hodgkin lymphoma 2356 (19.3) 2695 (65.2) 4415 (118.0) 4588 (199.6) 3874 (244.1) 985 (211.0) 18912 (77.3)
Hodgkin disease 2402 (19.6) 673 (16.3) 482 (12.9) 306 (13.3) 201 (12.7) 57 (12.2) 4122 (16.9)
Multiple myeloma 175 (1.4) 683 (16.5) 1881 (50.3) 2438 (106.0) 2396 (151.0) 601 (128.9) 8175 (33.4)
Acute leukemia 911 (7.4) 350 (8.5) 505 (13.5) 365 (15.9) 245 (15.4) 51 (10.9) 2426 (9.9)
CLL 98 (0.8) 546 (13.2) 1829 (48.9) 2429 (105.7) 2355 (148.4) 744 (159.5) 8001 (32.7)
All cancers 28568 (233.6) 45891 (1109.6) 144782 (3870.3) 187083 (8138.0) 146201 (9213.3) 31051 (6653.2) 583576 (2386.2)
Women
Lip, oral cavity, pharynx 563 (4.7) 1634 (37.9) 2628 (67.4) 1695 (64.4) 1457 (60.9) 769 (69.6) 8745 (33.1)
Esophagus 63 (0.5) 181 (4.2) 376 (9.6) 318 (12.1) 411 (17.2) 121 (11.0) 1470 (5.6)
Stomach 203 (1.7) 335 (7.8) 604 (15.5) 913 (34.7) 1366 (57.1) 734 (66.5) 4155 (15.7)
Colon-rectum 1614 (13.3) 4616 (107.1) 10375 (266.0) 13060 (496.4) 17589 (734.8) 9313 (843.3) 56567 (214.0)
Liver 109 (0.9) 177 (4.1) 438 (11.2) 444 (16.9) 510 (21.3) 116 (10.5) 1795 (6.8)
Pancreas 177 (1.5) 332 (7.7) 808 (20.7) 968 (36.8) 976 (40.8) 272 (24.6) 3534 (13.4)
Larynx 102 (0.8) 280 (6.5) 450 (11.5) 353 (13.4) 272 (11.3) 85 (7.7) 1542 (5.8)
Lung 776 (6.4) 2653 (61.5) 4004 (102.7) 2970 (112.9) 2316 (96.7) 428 (38.7) 13147 (49.7)
Skin melanoma 5254 (43.4) 3872 (89.8) 4544 (116.5) 3675 (139.7) 3275 (136.8) 1599 (144.8) 22219 (84.0)
Breast 19808 (163.8) 46379 (1075.6) 56394 (1445.7) 49397 (1878.0) 35032 (1463.5) 12746 (1154.1) 219756 (831.3)
Cervix uteri 4487 (37.1) 3353 (77.8) 1897 (48.6) 1215 (46.2) 1063 (44.4) 360 (32.6) 12374 (46.8)
Corpus uteri 434 (3.6) 2136 (49.5) 6897 (176.8) 7662 (291.2) 6105 (255.0) 1525 (138.1) 24758 (93.7)
Ovary 1218 (10.1) 2296 (53.3) 3539 (90.7) 3056 (116.2) 2208 (92.2) 541 (49.0) 12858 (48.6)
Bladder 76 (0.6) 279 (6.5) 675 (17.3) 1166 (44.3) 1926 (80.5) 1083 (98.1) 5205 (19.7)
Kidney 636 (5.3) 1304 (30.2) 2387 (61.2) 2718 (103.3) 3103 (129.6) 809 (73.3) 10957 (41.4)
Brain, CNS 1059 (8.8) 585 (13.6) 562 (14.4) 385 (14.6) 230 (9.6) 59 (5.3) 2879 (10.9)
Thyroid 7155 (59.2) 5678 (131.7) 6296 (161.4) 3077 (117.0) 1430 (59.7) 159 (14.4) 23795 (90.0)
Non-Hodgkin lymphoma 1490 (12.3) 1941 (45.0) 3423 (87.7) 3850 (146.3) 4053 (169.3) 1250 (113.2) 16006 (60.5)
Hodgkin disease 2544 (21.0) 400 (9.3) 293 (7.5) 194 (7.4) 156 (6.5) 56 (5.0) 3642 (13.8)
Multiple myeloma 132 (1.1) 527 (12.2) 1351 (34.6) 1930 (73.4) 2403 (100.4) 808 (73.1) 7151 (27.0)
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and thyroid cancers plus melanoma and Hodgkin disease.
For lip-mouth-pharynx, lung, esophagus, and larynx can-
cers, there were decreases in men but increases in women.
Total prevalence
The total prevalence amounted to 3 million persons:
1,570,000 men and 1,412,000 women; i.e., respectively,
6.4% and 5.3% of the general French population (Table 3).
In men, prostate cancer accounted for one-third of all
prevalent cases (2.1% of the adult male population). In
women, breast cancer accounted for 46% of all prevalent
cases (2.4% of the adult female population). In both men
and women, colorectal cancer accounted for nearly 10%
of the cases.
The distribution of the cases according to the cancer
sites varied with age. In men, testis cancer was the most
frequent between ages 15 and 44 and lip-mouth-pharynx
cancer the most frequent between ages 45 and 54. After
age 55, prostate cancer was the most frequent: it concerned
more than 10% of the general population aged ≥75 years. In
women, breast cancer was the most frequent in all age
groups. The prevalence of breast cancer exceeded 5% of the
general population aged 65 to 84 years. The second leading
cancers were thyroid cancer in the 15–54 age group and
colorectal cancer after aged 55; the latter affected 3% of the
population aged ≥85 years.
Discussion
Cancer is a high-burden disease because it affects a high
number of individuals and has social and economic con-
sequences. This life-threatening or long-duration disease
(depending on the site) requires regular evaluation and
anticipation of future needs, especially in terms of
healthcare and surveillance.
In France, in 2008, the number of persons with cancer
or having had a cancer was close to 3 million, which is
nearly 5% of the adult population. The diagnosis of more
than one-third of the prevalent cases was made 5 years
before and that of 40% made 6 to 10 years before. The
cancers with the highest partial and total prevalence
were prostate, breast, and colon-rectum cancers. The
total prevalence was high in the elderly: more than 30%
of men and 11% of women aged ≥ 85 have had cancer.
The partial prevalence was estimated using a classical
approach; i.e., annual estimations of incidence by age
and observed survival probabilities [6]. Here, this ap-
proach had the advantage of using nationwide incidence
estimations that are considered valid [14] but it assumed
that the incidence/mortality ratio of the registry area is
representative of the National ratio. The modeling made
it also possible to take into account recent changes in
trends [15], especially the stabilization of breast cancer
incidence and the marked decrease in prostate cancer
Table 1 Partial cancer prevalence at five years by sex and age of the adult French population (Continued)
Acute leukemia 830 (6.9) 389 (9.0) 435 (11.2) 379 (14.4) 228 (9.5) 68 (6.1) 2329 (8.8)
CLL 63 (0.5) 368 (8.5) 1143 (29.3) 1723 (65.5) 2196 (91.7) 865 (78.3) 6357 (24.0)
All cancers 51897 (429.1) 82884 (1922.2) 115001 (2948.1) 106883 (4063.0) 96079 (4013.7) 37580 (3402.7) 490324 (1854.8)
* Number of cases (proportion per 100 000 persons) - CNS: Central nervous system - CLL: Chronic lymphocytic leukemia.
Figure 1 Breakdown of the prevalent cases at 10 years in men according to the time since diagnosis (France, 2008).
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incidence since 2004–2005. The survival rate stemming
from the registries was also assumed to be a proxy for
the National rate. Indeed, the survival data stemmed
from 12 Départements (13% of the French population),
which is deemed to be acceptably representative.
The analyses of the case distributions according to the
time since diagnosis and to the change in prevalence
over time are complex because they depend on the ini-
tial levels and on the changes in incidence and overall
survival, the latter depending itself on cancer-related
and other death causes.
Although the prognosis influences the distribution of
cases according to the time since diagnosis –a good
prognosis led to a high number of prevalent cases be-
yond 5 years– there are nevertheless particular circum-
stances that may be explained by changes in incidence.
For example, larynx cancer in men, that had a much
lower survival rate than skin melanoma [9], had also a
higher prevalence beyond 5 years. This can be explained
by the inverse trends in incidence of these two cancers:
a decrease in larynx cancer vs. an increase in melanoma
[15] in a context of stable survival [16]; this translated into
higher recent incidence cases of melanoma vs. larynx
cancer. The age at incidence influences also the distri-
bution of prevalence according to the time since diag-
nosis. For example, though it has a good prognosis,
prostate cancer presents a distribution that is not fa-
vorable because patients are diagnosed late in life,
which results in a high number of deaths from other
causes than cancer.
The changes in prevalence observed between 2002 and
2008 can be explained by changes in the incidence of
some cancers. Indeed, the decrease or stabilization in
the incidence of alcohol- and tobacco-related tumors
(lip-mouth-pharynx, lung, esophagus, and larynx cancers)
in men and their increase in women [15] may explain the
sex-linked changes in the prevalence of these cancers. The
increase in the incidence of skin melanoma, in which the
effect of early diagnosis cannot be distinguished from that
of an increase in exposure [17], resulted also in an in-
crease in prevalence. The prevalence of thyroid cancer
was also on the rise, especially in women. This may be ex-
plained by the sharp increase in the incidence of this can-
cer, the greatest proportion of which results from the
diagnosis of good-prognosis tumors in relatively young
subjects [18].
The increase in cancer prevalence in France between
2002 and 2008 is largely attributable to changes in the
numbers of breast and prostate cancers. The change in
the prevalence of these two cancers can be explained by
an increase, up to a recent period, in incidence [15] ac-
companied by improved survivals [9]. As in thyroid
cancer, this increase concerns cases with very good
prognoses. More generally, in a context of increase in
incidence, De Angelis et al. [19] have shown that this
increase may be mainly explained by a change in inci-
dence. When incidence plateaus or decreases, changes
in survival are the main explanations for changes in
prevalence.
Recent changes in cancer incidence and mortality may
explain the differences between the present partial
prevalence estimations and those provided by Bray
et al. [6], these differences being of various magnitudes
according to the cancer site. The present study is based
on observed incidence data from cancer registries up to
2008 and on cancers diagnosed between 1995 and 2004
Figure 2 Breakdown of the prevalent cases at 10 years in women according to the time since diagnosis (France, 2008).
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27600 25470 −16.7 5.8 3.5 −7.3 6920 8745 15.5 6.0 5.1 26.5
Esophagus 5800 5655 −11.7 6.3 3.8 −1.6 940 1470 43.7 7.9 6.3 58.0
Stomach 7680 7448 −14.4 8.3 3.7 −2.4 4870 4155 −23.9 6.3 3.4 −14.2
Colon-rectum 59280 64297 −3.3 7.8 4.1 8.7 49690 56567 2.8 6.7 4.6 14.1
Liver 4960 7359 39.8 5.4 5.8 50.9 1220 1795 40.2 3.3 6.0 49.4
Pancreas 2370 3592 42.1 5.6 5.9 53.6 2540 3534 30.9 4.6 5.6 41.2
Larynx 10430 10684 −6.9 5.5 3.9 2.6 1150 1542 21.7 6.7 5.3 33.7
Lung 31830 35690 3.0 5.7 4.3 13.0 8100 13147 53.5 3.6 6.5 63.6
Skin
melanoma
11750 17893 42.2 4.2 5.8 52.2 16420 22219 26.7 3.2 5.4 35.3
Breast 183780 219756 10.2 4.6 4.8 19.6
Cervix uteri 12600 12374 −6.1 0.6 3.9 −1.6
Corpus uteri 21830 24758 3.3 5.8 4.5 13.6
Ovary 12540 12858 −5.9 4.4 4.1 2.6
Prostate 153380 265359 59.2 7.4 6.6 73.2
Bladder 23120 26344 1.2 8.8 4.4 14.3 4430 5205 6.5 6.7 4.7 17.9
Kidney 16020 21372 21.7 6.4 5.1 33.2 8570 10957 18.3 4.4 5.1 27.8
Thyroid 4890 7378 42.1 2.5 5.7 50.3 18040 23795 25.0 1.6 5.3 31.8
Non-Hodgkin
lymphoma
12050 18912 46.4 5.3 6.0 57.8 11290 16006 32.1 4.3 5.7 42.1
Hodgkin
disease
2970 4122 32.6 −1.6 5.2 36.2 2730 3642 30.7 −1.5 5.4 34.6
Multiple
myeloma
5640 8175 32.2 7.7 5.6 45.4 5280 7151 24.5 5.9 5.4 35.9
All cancers 424680 583576 25.9 6.5 5.3 37.7 406900 490324 11.3 4.6 4.8 20.8












with follow-ups until 2007 whereas, in the study of Bray
et al., the incidence data did not extend beyond 2003 and
the cancers were diagnosed between 1994 and 1999 with
follow-ups until 2003. Besides, the longer surveillance
period allowed here estimations of partial prevalence at
ten years.
Table 3 Total cancer prevalence by sex and age of the adult French population
Sex and site [15;44] [45;54] [55;64] [65;74] [75;84] 85 + 15-85+
Men
Lip, oral cavity, pharynx 2286 (18.7)* 15788 (381.7) 44194 (1181.4) 48011 (2088.5) 44120 (2780.4) 11063 (2370.4) 165462 (676.6)
Esophagus 76 (0.6) 1380 (33.4) 4772 (127.6) 6022 (262.0) 6058 (381.8) 943 (202.1) 19244 (78.7)
Stomach 336 (2.7) 1517 (36.7) 3898 (104.2) 6325 (275.1) 7783 (490.5) 2827 (605.7) 22686 (92.8)
Colon-rectum 2293 (18.8) 8330 (201.4) 27561 (736.8) 45913 (1997.3) 58893 (3711.3) 20558 (4404.9) 163548 (668.7)
Larynx 392 (3.2) 3510 (84.9) 10252 (274.1) 11889 (517.2) 10271 (647.3) 2298 (492.4) 38612 (157.9)
Lung 1180 (9.7) 6343 (153.4) 17011 (454.7) 21498 (935.2) 14615 (921.0) 0 (0.0) 60647 (243.5)
Skin melanoma 5825 (47.6) 6688 (161.7) 9640 (257.7) 8761 (381.1) 7569 (477.0) 2493 (534.2) 40976 (167.5)
Prostate 167 (1.4) 8586 (207.6) 86683 (2317.2) 180306 (7843.5) 185032 (11660.4) 47925 (10268.7) 508699 (2080.0)
Testis 18144 (148.4) 12246 (296.1) 7257 (194.0) 2458 (106.9) 881 (55.5) 95 (20.4) 41081 (168.0)
Bladder 409 (3.3) 2913 (70.4) 12234 (327.0) 21443 (932.8) 30118 (1898.0) 11324 (2426.3) 78441 (320.7)
Kidney 1633 (13.4) 5093 (123.1) 12081 (322.9) 14930 (649.5) 14082 (887.4) 3085 (661.0) 50904 (208.1)
Brain and other CNS 2644 (21.6) 2554 (61.8) 3179 (85.0) 2753 (119.8) 1646 (103.7) 39 (8.4) 12815 (52.4)
Thyroid 4034 (33.0) 4222 (102.1) 5632 (150.6) 3414 (148.5) 1706 (107.5) 228 (48.9) 19236 (78.7)
Non-Hodgkin lymphoma 5906 (48.3) 7687 (185.9) 11912 (318.4) 12496 (543.6) 11225 (707.4) 3069 (657.6) 52295 (213.8)
Hodgkin disease 6418 (52.5) 4742 (114.7) 3739 (100.0) 1640 (71.3) 1060 (66.8) 251 (53.8) 17850 (73.0)
Multiple myeloma 281 (2.3) 1141 (27.6) 3285 (87.8) 4565 (198.6) 5078 (320.0) 1217 (260.8) 15567 (63.7)
CLL 115 (0.9) 842 (20.4) 3379 (90.3) 5546 (241.3) 6599 (415.9) 2137 (457.9) 18618 (76.1)
All cancers 59874 (489.7) 99003 (2393.7) 279135 (7461.8) 450169 (19582.9) 533911 (33646.2) 148788 (31880.2) 1570880 (6423.3)
Women
Lip, oral cavity, pharynx 1219 (10.1) 4150 (96.2) 8128 (208.4) 7170 (272.5) 7252 (303.0) 3912 (354.2) 31831 (120.4)
Esophagus 79 (0.7) 290 (6.7) 764 (19.6) 973 (37.0) 926 (38.7) 259 (23.5) 3291 (12.4)
Stomach 325 (2.7) 734 (17.0) 1566 (40.1) 2320 (88.2) 4163 (173.9) 2331 (211.1) 11439 (43.3)
Colon-rectum 2710 (22.4) 8494 (197.0) 22545 (578.0) 34293 (1303.5) 54171 (2263.0) 32922 (2980.9) 155135 (586.8)
Larynx 162 (1.3) 523 (12.1) 1092 (28.0) 1229 (46.7) 1200 (50.1) 406 (36.8) 4612 (17.4)
Lung 1199 (9.9) 3631 (84.2) 5928 (152.0) 5185 (197.1) 2880 (120.3) 0 (0.0) 18823 (62.7)
Skin melanoma 10791 (89.2) 11171 (259.1) 14507 (371.9) 11986 (455.6) 11008 (459.9) 5144 (465.8) 64607 (244.4)
Breast 28156 (232.8) 90633 (2101.9) 168594 (4322.0) 168779 (6415.5) 137517 (5744.8) 51739 (4684.6) 645418 (2441.5)
Cervix uteri 9051 (74.8) 13615 (315.8) 15171 (388.9) 13428 (510.4) 13129 (548.5) 4887 (442.5) 69281 (262.1)
Corpus uteri 698 (5.8) 3510 (81.4) 14047 (360.1) 24405 (927.7) 28826 (1204.2) 11698 (1059.2) 83184 (314.7)
Ovary 2874 (23.8) 5138 (119.2) 9305 (238.5) 8790 (334.1) 6443 (269.2) 0 (0.0) 32550 (122.0)
Bladder 152 (1.3) 536 (12.4) 1492 (38.2) 2837 (107.8) 5482 (229.0) 3232 (292.6) 13731 (51.9)
Kidney 1184 (9.8) 2501 (58.0) 5157 (132.2) 7030 (267.2) 9620 (401.9) 2822 (255.5) 28314 (107.1)
Brain and other CNS 2512 (20.8) 2251 (52.2) 2574 (66.0) 2334 (88.7) 1719 (71.8) 82 (7.4) 11472 (43.4)
Thyroid 14566 (120.4) 15207 (352.7) 19568 (501.6) 11608 (441.2) 7239 (302.4) 1371 (124.1) 69559 (263.1)
Non-Hodgkin lymphoma 3676 (30.4) 5076 (117.7) 8692 (222.8) 10427 (396.3) 12323 (514.8) 4573 (414.1) 44767 (169.3)
Hodgkin disease 6501 (53.8) 3555 (82.4) 2466 (63.2) 1363 (51.8) 874 (36.5) 318 (28.8) 15077 (57.0)
Multiple myeloma 220 (1.8) 868 (20.1) 2503 (64.2) 3732 (141.9) 4902 (204.8) 1444 (130.7) 13669 (51.7)
CLL 82 (0.7) 578 (13.4) 2160 (55.4) 3884 (147.6) 5980 (249.8) 2667 (241.5) 15351 (58.1)
All cancers 93760 (775.3) 181142 (4201.0) 323253 (8286.8) 347359 (13203.5) 348636 (14564.4) 118133 (10696.1) 1412283 (5342.3)
*Number of cases (proportion per 100 000 persons) - CNS: Central nervous system - CLL: Chronic lymphocytic leukemia.
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The present estimations of the total prevalence used
the net risks of incidence and death per cancer, which
assumes the same frequency of death from other causes
than cancer in diseased and non-diseased populations
[11]. A comparison with the Nordic observations [20]
and the US estimations [21], based on the “partial preva-
lence/total prevalence” ratio (partial prevalence at 5 and
10 years; results not shown), found close values of that
ratio for most cancer sites. The most marked differences
in the “partial prevalence/total prevalence” ratios may
have various causes. These ratios are indeed particularly
low in France for lip-mouth-pharynx and esophagus
cancers which are particularly impacted by the onset of
a second cancer [22-24]. Therefore, the risk of cancer
may not necessarily match the death from cancer be-
cause death may be attributable to the second but not
the first cancer. The ways incidence changes in different
countries may also explain the differences in “partial
prevalence/total prevalence” ratios; e.g.; the incidence of
lip-mouth-pharynx and esophagus cancers decreased in
France but increased in the Nordic countries and the
United States. The reduction of the input in prevalence
induces mechanically an increase in the proportion of
prevalent cases with old diagnosis. Although the present
estimations regarding these cancers may be biased by
the potential presence of multiple cancers, it is difficult
to quantify this bias.
Total prevalence was not estimated for liver cancer,
pancreas cancer, and acute leukemia because the net risk
of death from each of these cancers was higher than that
of incidence. In fact, a death/incidence ratio > 1 is associ-
ated with a poor quality of mortality data and, sometimes,
incidence data. Regarding liver cancer, an overestimation
of mortality is possible because a number of secondary
cancers may have been considered, at death, as primary
cancers [8]. An overestimation may also occur when
deaths from jaundice are registered as deaths from liver or
pancreas cancer. The data relative to death from pancreas
cancer might have been unreliable too [25]. Similarly, a
lack of specificity regarding death registration with cause
“acute leukemia” may lead to an overestimation of death
from leukemia. Besides, an overestimation of mortality
may combine with underestimation of incidence. This
may occur with liver and pancreas cancer because of
the lack of clinical arguments to confirm the diagnoses
of cancer [26].
There were three cancer sites for which the net risk of
incidence was lower than the net risk of death from can-
cer in persons aged 85 years and more: lung cancer,
ovarian cancer, and central nervous system cancer. This
discordance between incidence and mortality may re-
ceive two explanations. The first is mechanical. Actually,
there is a sharp decrease in incidence after 80 years to-
gether with a persistent increase in mortality; this leads
to net risks of death higher than incidence. This occurs
in a context where the prevalence relative to these three
cancers is poorly fuelled by new cases because of the
bad prognoses of these cancers at such old ages. The
second is epidemiological. Indeed, part of the deaths at-
tributed to lung cancer may, in fact, be due to lung me-
tastases derived from past primary non-pulmonary
cancers. In elderly people, some lung cancers are not
registered as incident cancers because of insufficient
clinical investigations whereas these cases may contrib-
ute to the number of deaths from lung cancer. Similarly,
in elderly women, some ovarian cancers are not fully in-
vestigated, which biases their incidence [26]. Finally, the
incidence of central nervous system cancers corresponds
to invasive types whereas the benign types may also con-
tribute to the number of deaths; this may induce discord-
ance between the net risk of incidence and mortality, a
discordance that may aggravate at advanced ages.
The data on incidence and mortality used here for es-
timating total prevalence cover the whole 1975–2008
period; that is 34 years. This period provides a sufficient
hindsight on the majority of cancer sites for which the
median age at diagnosis is over 60 years. However, this
period may not be sufficient for cancers of good progno-
sis that occur mainly in young adults such as testis can-
cer or Hodgkin disease. The total prevalence for these
two cancers is thus probably underestimated.
As already mentioned, uncertainties about the total
prevalence of some cancer are linked to poor quality of
incidence or mortality data registration. Thus, in case of
incidence underestimation (liver or pancreas cancer), the
partial prevalence may be biased and should be inter-
preted with caution too because it relies on incidence
and survival.
In addition, in principle, an interval estimation of
prevalence seems necessary. Unfortunately, such estima-
tion requires the knowledge of observed prevalence and
some approximations [27]. The methodology used here
for total or partial prevalence may be further refined by
future works.
The part of a partial prevalence within the total preva-
lence gives an indication of the proportion of patients who
continue to require care and surveillance (prevalence at
5 years, nearly one third of prevalent cases), the propor-
tion of those who require less care or surveillance, and
even those who are cured (prevalence past 10 years, nearly
40% of cases).
Conclusion
Prevalence is a key epidemiologic indicator that quanti-
fies the importance of the group of patients who have
had cancer. In France, in 2008, more the 3 millions were
concerned. The distribution of cancer cases according to
the time since diagnosis provides an evaluation of the
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needs in terms of treatment and surveillance among
prevalent cases. Furthermore, prevalent cases may have
difficulties due to the social and economic consequences
of cancer. The present estimations update the French
prevalence data. It demonstrated the importance of
using the most updated data (incidence and survival) in
the estimation process. Finally, such estimations should
be regularly made because of changes in the trends of
incidence and improvements of survival.
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